171 related articles for article (PubMed ID: 15992909)
41. Seed migration in prostate brachytherapy: a re-implant case report.
Di Muzio N; Longobardi B; Losa A; Mangili P; Nava LD; Rigatti P; Calandrino R; Villa E; Guazzoni G
Br J Radiol; 2003 Dec; 76(912):913-5. PubMed ID: 14711781
[TBL] [Abstract][Full Text] [Related]
42. [Iodin 125 seed migration after prostate brachytherapy: a study of 170 patients].
Chauveinc L; Osseili A; Flam T; Thiounn N; Rosenwald JC; Savignoni A; Cosset JM
Cancer Radiother; 2004 Aug; 8(4):211-6. PubMed ID: 15450513
[TBL] [Abstract][Full Text] [Related]
43. The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy.
Niehaus A; Merrick GS; Butler WM; Wallner KE; Allen ZA; Galbreath RW; Adamovich E
Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):136-43. PubMed ID: 16198062
[TBL] [Abstract][Full Text] [Related]
44. Predictive factors for acute and late urinary toxicity after permanent prostate brachytherapy: long-term outcome in 712 consecutive patients.
Keyes M; Miller S; Moravan V; Pickles T; McKenzie M; Pai H; Liu M; Kwan W; Agranovich A; Spadinger I; Lapointe V; Halperin R; Morris WJ
Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1023-32. PubMed ID: 19111402
[TBL] [Abstract][Full Text] [Related]
45. Migration of prostate brachytherapy seeds to the vertebral venous plexus.
Nakano M; Uno H; Gotoh T; Kubota Y; Ishihara S; Deguchi T; Hayashi S; Matsuo M; Tanaka O; Hoshi H
Brachytherapy; 2006; 5(2):127-30. PubMed ID: 16644468
[TBL] [Abstract][Full Text] [Related]
46. (125)I monotherapy using D90 implant doses of 180 Gy or greater.
Kao J; Stone NN; Lavaf A; Dumane V; Cesaretti JA; Stock RG
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):96-101. PubMed ID: 17980505
[TBL] [Abstract][Full Text] [Related]
47. Reduction of radioactive seed embolization to the lung following prostate brachytherapy.
Tapen EM; Blasko JC; Grimm PD; Ragde H; Luse R; Clifford S; Sylvester J; Griffin TW
Int J Radiat Oncol Biol Phys; 1998 Dec; 42(5):1063-7. PubMed ID: 9869230
[TBL] [Abstract][Full Text] [Related]
48. Effect of edema on postimplant dosimetry in prostate brachytherapy using CT/MRI fusion.
Tanaka O; Hayashi S; Matsuo M; Nakano M; Uno H; Ohtakara K; Miyoshi T; Deguchi T; Hoshi H
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):614-8. PubMed ID: 17869675
[TBL] [Abstract][Full Text] [Related]
49. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
Mabjeesh NJ; Chen J; Stenger A; Matzkin H
Urology; 2007 Sep; 70(3):548-53. PubMed ID: 17905113
[TBL] [Abstract][Full Text] [Related]
50. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Shinohara K; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):341-6. PubMed ID: 18597953
[TBL] [Abstract][Full Text] [Related]
51. Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysis.
Al-Qaisieh B; Smith DW; Brearley E; St Clair S; Bownes P
Radiother Oncol; 2007 Aug; 84(2):140-7. PubMed ID: 17588696
[TBL] [Abstract][Full Text] [Related]
52. Accurate and efficient detection of pulmonary seed embolization in prostate iodine-125 permanent brachytherapy with a collimated gamma scintillation survey meter.
Chen QS; Blair HF
Med Phys; 2003 May; 30(5):785-90. PubMed ID: 12772985
[TBL] [Abstract][Full Text] [Related]
53. Radioactive implant migration in patients treated for localized prostate cancer with interstitial brachytherapy.
Older RA; Synder B; Krupski TL; Glembocki DJ; Gillenwater JY
J Urol; 2001 May; 165(5):1590-2. PubMed ID: 11342923
[TBL] [Abstract][Full Text] [Related]
54. Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
Tanaka N; Asakawa I; Kondo H; Tanaka M; Fujimoto K; Hasegawa M; Konishi N; Hirao Y
Int J Urol; 2009 Jan; 16(1):70-4. PubMed ID: 19120529
[TBL] [Abstract][Full Text] [Related]
55. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
56. Prostate brachytherapy seed migration to a left varicocele.
Sugawara A; Nakashima J; Kunieda E; Nagata H; Mizuno R; Seki S; Shiraishi Y; Kouta R; Oya M; Shigematsu N
Brachytherapy; 2012; 11(6):502-6. PubMed ID: 22192493
[TBL] [Abstract][Full Text] [Related]
57. [PSA bounce after permanent implant prostate brachytherapy may mimic a biochemical failure].
Toledano A; Chauveinc L; Flam T; Thiounn N; Solignac S; Timbert M; Rosenwald JC; Cosset JM
Cancer Radiother; 2007 May; 11(3):105-10. PubMed ID: 17158082
[TBL] [Abstract][Full Text] [Related]
58. Radiation dose to the internal pudendal arteries from permanent-seed prostate brachytherapy as determined by time-of-flight MR angiography.
Gillan C; Kirilova A; Landon A; Yeung I; Pond G; Crook J
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):688-93. PubMed ID: 16626892
[TBL] [Abstract][Full Text] [Related]
59. Intraoperative real-time planned conformal prostate brachytherapy: post-implantation dosimetric outcome and clinical implications.
Zelefsky MJ; Yamada Y; Cohen GN; Sharma N; Shippy AM; Fridman D; Zaider M
Radiother Oncol; 2007 Aug; 84(2):185-9. PubMed ID: 17692978
[TBL] [Abstract][Full Text] [Related]
60. Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes.
Stone NN; Potters L; Davis BJ; Ciezki JP; Zelefsky MJ; Roach M; Fearn PA; Kattan MW; Stock RG
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1472-7. PubMed ID: 17689026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
